WO2018065627A1 - Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 - Google Patents
Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 Download PDFInfo
- Publication number
- WO2018065627A1 WO2018065627A1 PCT/EP2017/075682 EP2017075682W WO2018065627A1 WO 2018065627 A1 WO2018065627 A1 WO 2018065627A1 EP 2017075682 W EP2017075682 W EP 2017075682W WO 2018065627 A1 WO2018065627 A1 WO 2018065627A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- oligonucleotide
- cells
- cancer
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03005—5'-Nucleotidase (3.1.3.5)
Definitions
- CD73 The present disclosure refers to an immunosuppression-reverting oligonucleotide hybridizing with a nucleic acid sequence of an ectoenzyme (NT5E or CD73) and to a pharmaceutical composition comprising such immunosuppression-reverting
- immune checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or down a signal.
- Immune checkpoint modulators i.e., stimulators or inhibitors are for example directed to one or more of CTLA-4, PD-1, PD- LI, LAG- 3, VISTA, A2AR, BTLA, IDO, CD39, CD73, STAT3, TD02, TIM-3, MICA, NKG2A, KIR, TIGIT, TGF-beta, Ox40, GITR, CD27, CD 160, 2B4 and 4- IBB.
- CD73 needs to be considered as one novel and promising candidate to improve immunity towards different types of cancers.
- CD73 is an ectoenzyme (NTPdase) and catalyzes the conversion of AMP to immunosuppressive adenosine.
- CD73 acts in concert but downstream of CD39, known to convert ATP to ADP and ADP to AMP.
- Adenosine exerts its effects via adenosine receptor Al, adenosine receptor A2A, adenosine receptor AiB and adenosine receptor A3.
- the range of immune cells expressing adenosine receptors and therefore potentially affected by the immunomodulatory effects of adenosine include T lymphocytes, natural killer (NK) cells, NKT cells, macrophages, DCs, neutrophils, mast cells and B cells.
- CD73 is found in most tissues and many cell types including subsets of lymphocytes, macrophages, dendritic cells, endothelial cells and epithelial cells. Hypoxia induces CD73 mRNA, protein expression and increases CD73 activity in mouse microvascular endothelial cells. Particularly, CD73 is highly expressed in many different human (solid and hematologic) tumors, and its elevated expression and activity are associated with tumor invasiveness and metastasis and with shorter patient survival. The RNA expression and enzyme activity of CD73 are variable in different breast cancer cell lines.
- Dying cancer cells release ATP to the extracellular space in the tumor microenvironment.
- Living tumor cells express often high levels of CD39 and CD73 and convert ATP to the immunosuppressive adenosine.
- tumor cells are competent to perform uncontrolled proliferation and expansion.
- A2A or A2B receptors on lymphocytes By binding to A2A or A2B receptors on lymphocytes, adenosine mediates an immunosuppressive signal towards these cells.
- T cells are inhibited in their proliferation, cytotoxic cytokine production and activation.
- NK cells show reduced cytotoxic potential.
- Adenosine induces alternative activation in macrophages (immune suppressive M2 phenotype) resulting in reduced proinflammatory cytokine production but increased generation of the immunosuppressive cytokine IL-10.
- the important role of CD73 as relevant therapeutic target in different tumors is underlined by the fact that tumor models using CD73 or A2A receptor knockout mice reveal improved disease outcome.
- Anti-human CD73 monoclonal antibodies such as anti-CD73-antibodies of Innate Pharma (e.g., Innate Pharma Poster #iph_poster_aarc2016_cd73) are currently under pre-clinical investigation in immune-oncology cell-based assays. However, because of steric hindrance monoclonal antibodies against CD73 might fail to localize to the tumor microenvironment.
- non-hydrolysable small molecular inhibitors of CD73 such as AMPCP (adenosine 5'-(a,6-methylene)diphosphate; e.g., Structure20, 2161-2173, December 5, 2012) an ADP analog competitively inhibiting the CD73 activity, have been tested in vitro and in vivo in animal models but relatively high concentrations and repetitive dosing are needed to successfully block CD73 enzymatic activity.
- AMPCP adenosine 5'-(a,6-methylene)diphosphate
- Immune therapies have resulted in long-term remission, but only of small patient groups so far. The reason may be that numerous immune checkpoints and optionally further immunosuppressive mechanisms are involved in the interaction between for example the immune system and the tumor cells. The combination of immune checkpoints and potential other mechanisms may vary depending on the tumor and individual conditions of a subject to escape the body's defenses. For the inhibition of several immunosuppressive mechanisms common approaches using an antibody and/or a small molecule are not or hardly suitable as the molecular target is located intracellularly or does not have enzymatic activity. Accordingly, an agent which is safe and effective in inhibiting the function of an "immune checkpoint" such as CD73 would be an important addition for the treatment of patients suffering from diseases or conditions affected for example by the activity of this enzyme.
- Oligonucleotides of the present invention are very successful in the inhibition of the expression and activity of CD73, respectively.
- the mode of action of an oligonucleotide differs from the mode of action of an antibody or small molecule, and oligonucleotides are highly advantageous regarding for example
- CD73 expression on cancer and immune cells on mRNA-level by antisense-oligonucleotides is a promising state-of-the-art approach to develop and improve for example immunotherapies against different cancers and immune diseases, respectively.
- the present invention refers to an oligonucleotide such as an immunosuppression- reverting oligonucleotide comprising about 10 to 20 nucleotides, wherein at least one of the nucleotides is modified.
- the oligonucleotide hybridizes for example with a nucleic acid sequence of an ectoenzyme CD73 of SEQ ID NO. 1 (human) and/or a sequence of SEQ ID NO.2 (mouse).
- the modified nucleotide is for example selected from the group consisting of a bridged nucleic acid (e.g., LNA, cET, ENA, 2'Fluoro modified nucleotide or 2O-Methyl modified nucleotide).
- the oligonucleotide inhibits at least 50 % of the CD73 expression and in some embodiments the oligonucleotide inhibits the expression of CD73 at a nanomolar concentration.
- Antisense oligonucleotides have significant advantages in comparison to RNAi.
- Antisense oligonucleotides can be transfected without transfecting reagent in vitro and thus, the transfection is closer to in vivo conditions than transfections using transfecting reagents which are obligatory for the transfection of RNAi. In vivo systemic
- RNAi regularly show off- target effects of passenger strands which likewise can initiate RNAi passenger strand RISC loading is a significant concern for RNAi drugs because the passenger strand could direct RNAi activity towards unintended targets, resulting in toxic side effects" (see Chackalamannil, Rotella, Ward, Comprehensive Modicinal Chemistry III Elsevier, 03.06.2017).
- Antisense oligonucleotides do not comprise a passenger strand.
- the present invention is further directed to a pharmaceutical composition comprising an immunosuppression-reverting oligonucleotide of the present invention and optionally a pharmaceutically acceptable carrier, excipient and/or dilutant.
- this pharmaceutical composition additionally comprises a chemotherapeutic such as platinum or gemcitabine, another oligonucleotide, an antibody and/or a small molecule which is for example effective in tumor treatment.
- the oligonucleotide of the present invention is in combination with another oligonucleotide, an antibody and/or a small molecule, either each of these compounds is separate or combined in a pharmaceutical composition, wherein the oligonucleotide, the antibody and/or the small molecule inhibits or stimulates an immune suppressive factor such as IDOl, ID02, CTLA-4, PD-1, PD-L1, LAG-3, VISTA, A2AR, CD39, CD73, STAT3, TD02, TIM-3, TIGIT, TGF-beta, BTLA, MICA, NKG2A, KIR, CD160, Chop, and/or Xbpl.
- the oligonucleotide, the antibody and/or the small molecule inhibits or stimulates or an immune stimulatory factor such as 4- IBB, Ox40, KIR, GITR, CD27 and/or 2B4.
- the present invention relates to the use of the oligonucleotide or the pharmaceutical composition of the present invention in a method of preventing and/or treating a disorder, where a CD73 imbalance is involved.
- the disorder is for example an autoimmune disorder, for example autoimmune arthritis or gastrointestinal autoimmune diseases such as inflammatory bowel disease (IBD) or colitis, an immune disorder, for example an immune exhaustion due to chronic viral infections such as HIV infection, a cardiovascular disorder, an inflammatory disorder, for example a chronic airway inflammation, a bacterial, viral and/or fungal infection, for example sepsis or a Mycobacterium bovis infection, a liver disorder, a chronic kidney disorder, a psychiatric disorder and/or cancer.
- IBD inflammatory bowel disease
- an immune disorder for example an immune exhaustion due to chronic viral infections such as HIV infection
- a cardiovascular disorder an inflammatory disorder, for example a chronic airway inflammation, a bacterial, viral and/or fungal infection, for example sepsis or a
- CD73 has many physiological roles, such as regulation of barrier function, adaptation to hypoxia, ischemic preconditioning, anti- inflammation, leukocyte extravasation. Expression and activity of CD73 on cancer cells is associated with poor prognosis and may promote metastasis. CD73 facilitates the adhesion, migration, invasion of human breast cancer cells and proliferation of glioma cells and these processes are dependent upon the enzyme's production of adenosine.
- the oligonucleotide or the pharmaceutical composition of the present invention is for example administered locally or systemically.
- Fig. 1 depicts the distribution of human (h)CD73 antisense oligonucleotide binding sites on the hCD73 mRNA of SEQ ID No. 1 (NM_002526.3) as well as their modification(s) and length.
- hCD73 antisense oligonucleotides were aligned to the hCD73 mRNA sequence of SEQ ID No. 1.
- the different grayscales indicate the different LNA
- Fig. 2A-2E depict hCD73 mRNA knockdown efficacy of hmCD73 antisense oligonucleotides in human cancer cell lines A- 172 (human glioblastoma) in a first and second screening round (Fig. 2A and 2B (parts 1 and 2)), and EFO-21 (human ovary cystadenocarcinoma;) in one screening round (Fig. 2C (parts 1 and 2)), in one murine cell line 4T1 (breast cancer) in one screening round (Fig. 2D (parts 1 and 2)) and human SKOV-3 (human ovarian adenocarcinoma cancer) cells in one screening round (Fig. 2E).
- A- 172, EFO-21, 4T1 and SKOV-3 cells were treated for 3 days with 10 ⁇ of the respective antisense oligonucleotide.
- Residual human or mouse CD73 mRNA expression relative to untreated cells is depicted. Expression values were normalized to expression values of the housekeeping gene GAPDH or HPRTl. Depicted is the mean of triplicate wells +/- SD.
- Fig. 3A and 3B show a correlation analysis of hmCD73 antisense oligonucleotide efficacy in human EFO-21 cells compared to human A- 172 cells (Fig. 3A) and human A- 172 cells compared to mouse 4T1 cells (Fig. 3B).
- Fig. 4A and 4B shows concentration dependent hmCD73 mRNA knockdown by selected hmCD73 antisense oligonucleotides in SKOV-3 cells and EFO-21 (human ovarian cancer), which were A05008HM (SEQ ID No. 4), A05009HM (SEQ ID No. 6), A05018HM (SEQ ID No. 3), A05026HM (SEQ ID No.
- SKOV-3 and EFO-21 cells were treated for 3 days with the indicated concentration of the respective antisense oligonucleotide. Residual hCD73 expression is depicted compared to untreated control cells (set as 100). hCD73 mRNA expression values were normalized to expression of the housekeeping gene HPRTl. Depicted is the mean of triplicate wells +/- SD.
- FIG. 5A to 5C depict hmCD73 mRNA knockdown efficacy of hmCD73 antisense oligonucleotides in human and mouse cancer cell lines.
- EFO-21 human ovary
- cystadenocarcinoma (Fig. 5A)
- SKOV-3 human ovarian adenocarcinoma
- 4T1 mouse breast cancer
- hCD73 mRNA expression values were normalized to expression of the housekeeping gene HPRTl. Residual hCD73 mRNA expression relative to untreated cells (set as 100) is depicted. Depicted is the mean of triplicate wells +/- SD.
- Fig. 7A and 7B depict a concentration-dependent hCD73 mRNA and protein knockdown by A05008HM (SEQ ID No. 4), A05018HM (SEQ ID No. 3) and A05028HM (SEQ ID No. 5).
- Analysis of protein expression and cell viability by flow cytometry of CD73 (Fig. 7A), and 7-AAD staining of SKOV-3 cells (Fig. 7B) was performed after treatment with the indicated antisense oligonucleotides for 6 days.
- As a control cells were similarly treated with negl.
- Median fluorescence intensity of CD73 protein expression Fig. 7A
- total dead cells (7-AAD positive cells) Fig. 7B
- Fig. 8 shows knockdown of CD73 protein expression on SKOV3 and EFO-21 cells after antisense oligonucleotide treatment.
- Fig. 9A-9D depict effects of hCD73 knockdown on extracellular pyrophosphate levels and cell viability by SKOV-3 and EFO-21 cells.
- Generation of pyrophosphate as an indirect measure for the production of adenosine was analyzed in cell supernatants from EFO-21 cells (Fig. 9A) and SKOV-3 cells (Fig. 9C), that were treated for 6 days with A05018HM (SEQ ID No. 3). Before measurement, exogenous AMP was added to the cells at 500 ⁇ at the indicated time points. Effect of the treatment with A05018HM (SEQ ID No. 3) on cell viability of EFO-21 cells (Fig. 9B) and SKOV-3 cells (Fig. 9D) was tested using the cell titer blue assay.
- Fig. 10A to IOC shows EFO-21 cells treated with the CD73-specific antisense
- oligonucleotide A05018HM black column
- control oligonucleotide S6 white column
- hCD73 protein expression was analyzed by flow cytometry.
- Fig. 10A depicts residual hCD73 expression relative to untreated cells (dotted column; set as 1).
- 300 ⁇ of AMP was added to cells or cell-free PBS (striped column) 6.5 h before termination.
- Fig. 10B shows relative AMP levels relative to cell-free AMP-supplemented PBS (set as 1) and
- Fig. IOC depicts absolute adenosine concentrations in cell
- Fig. 11A to 11C depict human CD4 + T cells labelled with cell proliferation dye, activated with anti-CD3 and treated with 5 ⁇ of the CD73 specific antisense oligonucleotide A05018HM (black column) or the control oligonucleotide S6 (white column) for a total treatment time of 5 days.
- vehicle control striped column
- cells were activated with anti-CD3 only.
- 300 ⁇ of AMP or vehicle were added to cells on day 3 and day 4 after start of oligonucleotide treatment.
- Fig. 11A shows CD73 protein expression
- Fig. 11B depicts proliferation
- Fig. 11 C shows absolute cell numbers of CD4 + T cells which were analyzed using Flow Cytometry on day 5 after start of oligonucleotide treatment. Depicted is the mean of triplicate wells +/- SD.
- Fig. 12 depicts in vivo effect of hmCD73 antisense oligonucleotide (A05027HM) treatment on mCD73 mRNA expression in mouse liver.
- the results depicted in Fig. 12 show mCD73 mRNA levels in livers of A05027HM- or vehicle- treated mice (white column).
- Fig. 13 shows hCD73 mRNA of SEQ ID No. 1 (NM_002526.3). Detailed description
- the present invention provides for the first time human and murine oligonucleotides which hybridize with mRNA sequences of the ectonucleotidase CD73 and inhibit the expression and activity, respectively, of CD73 for example on a tumor cell or a tumor - associated immune cell.
- the level of ATP increases and the level of its degradation products such as ADP, AMP and immunosuppressive Adenosine decreases. All these effects result in an increase of antitumoral immune cells, immune activation (e.g., via cytotoxic T cells or NK cells) and recognition and elimination of tumor cells, respectively.
- the oligonucleotides of the present invention represent an interesting and highly efficient tool for use in a method of preventing and/or treating disorders, where the CD73 expression and activity, respectively, is increased.
- Oligonucleotides of the present invention are for example antisense oligonucleotides consisting of or comprising 10 to 25 nucleotides, 10 to 15 nucleotides, 15 to 20 nucleotides, 12 to 18 nucleotides, or 14 to 17 nucleotides.
- the oligonucleotides for example consist of or comprise 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 25 nucleotides.
- the oligonucleotides of the present invention comprise at least one nucleotide which is modified.
- the modified nucleotide is for example a bridged nucleotide such as a locked nucleic acid (LNA, e.g., 2',4'-LNA), cET, ENA, a 2 luoro modified nucleotide, a 2 ⁇ - Methyl modified nucleotide or combinations thereof.
- LNA locked nucleic acid
- cET cET
- ENA ENA
- a 2 luoro modified nucleotide e.g., 2 ⁇ - Methyl modified nucleotide or combinations thereof.
- the oligonucleotide of the present invention comprises nucleotides having the same or different modifications.
- the oligonucleotide of the present invention comprises a modified phosphate backbone, wherein the phosphate is for example a phosphorothioate or methylphosphonate or both.
- the oligonucleotide of the present invention comprises the one or more modified nucleotide at the 3'- and/or 5'- end of the oligonucleotide and/or at any position within the oligonucleotide, wherein modified nucleotides follow in a row of 1, 2, 3, 4, 5, or 6 modified nucleotides, or a modified nucleotide is combined with one or more unmodified nucleotides.
- Table 1 presents embodiments of oligonucleotides comprising modified nucleotides for example LNA which are indicated by (+) and phosphorothioate (PTO) indicated by (*).
- oligonucleotides consisting of or comprising the sequences of Table 1 may comprise any other modified nucleotide and any other combination of modified and unmodified nucleotides. Oligonucleotides of Table 1 hybridize with mRNA of human and murine CD 73:
- Table 1 List of antisense oligonucleotides hybridizing with human and murine CD73 for example of SEQ ID No. 1 and SEQ ID No. 2, respectively.
- Negl is an antisense oligonucleotide representing a negative control which is not hybridizing with CD73 of SEQ ID No. 1 and SEQ ID No. 2.
- oligonucleotides of the present invention hybridize for example with mRNA of human or murine CD73 of SEQ ID No. 1 and/or SEQ ID No. 2. Such oligonucleotides are called CD73 antisense oligonucleotides.
- the oligonucleotide of the present invention inhibits at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of CD73 such as the, e.g., human or murine, CD73 expression.
- CD73 such as the, e.g., human or murine, CD73 expression.
- oligonucleotides of the present invention are immunosuppression-reverting
- oligonucleotides which revert immunosuppression for example in a cell, tissue, organ, or a subject.
- the oligonucleotide of the present invention inhibits the expression of CD73 at a nanomolar or micromolar concentration for example in a concentration of 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900 or 950 nM, or 1, 10 or 100 ⁇ .
- the oligonucleotide of the present invention is used in a
- the pharmaceutical composition further comprises a chemotherapeutic, another oligonucleotide, an antibody and/or a small molecule.
- the oligonucleotide or the pharmaceutical composition of the present invention is for use in a method of preventing and/or treating a disorder.
- the use of the oligonucleotide or the pharmaceutical composition of the present invention in a method of preventing and/or treating a disorder is combined with radiotherapy.
- the radiotherapy may be further combined with a chemotherapy (e.g., platinum, gemcitabine).
- the disorder is for example characterized by an CD73 imbalance, i.e., the CD73 level is increased in comparison to the level in a normal, healthy cell, tissue, organ or subject.
- the CD73 level is for example increased by an increased CD73 expression and activity, respectively.
- the CD73 level can be measured by any standard method such as immunohistochemistry, western blot, quantitative real time PCR or QuantiGene assay known to a person skilled in the art.
- oligonucleotide or a pharmaceutical composition of the present invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-a
- oligonucleotide is administered alone or in
- oligonucleotide of the present invention in combination with another immunosuppression-reverting oligonucleotide of the present invention and optionally in combination with another compound such as another oligonucleotide, an antibody, a small molecule and/or a chemotherapeutic (e.g., platinum, gemcitabine).
- another compound such as another oligonucleotide, an antibody, a small molecule and/or a chemotherapeutic (e.g., platinum, gemcitabine).
- the other oligonucleotide i.e., not being part of the present invention
- the antibody, and/or the small molecule are effective in preventing and/or treating an autoimmune disorder, for example autoimmune arthritis or
- gastrointestinal autoimmune diseases such as inflammatory bowel disease (IBD) or colitis
- an immune disorder for example an immune exhaustion due to chronic viral infections such as HIV infection, a cardiovascular disorder, an inflammatory disorder for example a chronic airway inflammation, a bacterial, viral and/or fungal infection for example sepsis or a Mycobacterium bovis infection, a liver disorder, a chronic kidney disorder, a psychiatric disorder (e.g., schizophrenia, bipolar disorders, Alzheimer's disease) and/or cancer.
- IBD inflammatory bowel disease
- colitis an immune disorder, for example an immune exhaustion due to chronic viral infections such as HIV infection, a cardiovascular disorder, an inflammatory disorder for example a chronic airway inflammation, a bacterial, viral and/or fungal infection for example sepsis or a Mycobacterium bovis infection, a liver disorder, a chronic kidney disorder, a psychiatric disorder (e.g., schizophrenia, bipolar disorders, Alzheimer's disease) and/or cancer.
- An oligonucleotide or a pharmaceutical composition of the present invention is used for example in a method of preventing and/or treating a solid tumor or a hematologic tumor.
- cancers preventable and/or treatable by use of the oligonucleotide or pharmaceutical composition of the present invention are breast cancer, lung cancer, malignant melanoma, lymphoma, skin cancer, bone cancer, prostate cancer, liver cancer, brain cancer, cancer of the larynx, gall bladder, pancreas, testicular, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma, reticulum cell sarcoma, liposarcoma, myeloma, giant cell tumor, small- cell lung tumor, islet cell tumor, primary brain tumor, meningioma, acute and chronic lymphocy
- retinoblastoma retinoblastoma
- soft tissue sarcoma malignant carcinoid
- topical skin lesion retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion
- oligonucleotides of the present invention are administered together, at the same time point for example in a pharmaceutical composition or separately, or on staggered intervals.
- one or more oligonucleotides of the present invention are administered together with another compound such as another oligonucleotide (i.e., not being part of the present invention), an antibody, a small molecule and/or a chemotherapeutic, at the same time point for example in a pharmaceutical composition or separately, or on staggered intervals.
- another compound such as another oligonucleotide (i.e., not being part of the present invention)
- an antibody i.e., not being part of the present invention
- a small molecule and/or a chemotherapeutic at the same time point for example in a pharmaceutical composition or separately, or on staggered intervals.
- oligonucleotide inhibits the expression and activity, respectively, of an immune suppressive factor and the other oligonucleotide (i.e., not being part of the present invention), the antibody and/or small molecule inhibits (antagonist) or stimulates
- the immune suppressive factor is for example selected from the group consisting of IDOl, ID02, CTLA-4, PD-1, PD-L1, LAG- 3, VISTA, A2AR, CD39, CD73, STAT3, TD02, TIM- 3, TIGIT, TGF-beta, BTLA, MICA, NKG2A, KIR, CD160, Chop, Xbpl and a combination thereof.
- the immune stimulatory factor is for example selected from the group consisting of 4-1BB, Ox40, KIR, GITR, CD27, 2B4 and a combination thereof.
- the immune suppressive factor is a factor whose expression and/or activity is for example increased in a cell, tissue, organ or subject.
- the immune stimulatory factor is a factor whose level is increased or decreased in a cell, tissue, organ or subject depending on the cell, tissue, organ or subject and its individual conditions.
- An antibody in combination with the oligonucleotide or the pharmaceutical composition of the present invention is for example an anti-PD-1 antibody, an anti-PD-Ll antibody, or a bispecific antibody.
- a small molecule in combination with the oligonucleotide or the pharmaceutical composition of the present invention is for example AMPCP (adenosine 5'-(a,6-methylene)diphosphate; e.g., Structure20, 2161-2173, December 5, 2012), which acts as an ADP analog and is therefore an competitive inhibitor of CD73 activity.
- a subject of the present invention is for example a mammalian, a bird or a fish.
- the following examples illustrate different embodiments of the present invention, but the invention is not limited to these examples.
- the following experiments are performed on cells endogenously expressing CD73, i.e., the cells do not represent an artificial system comprising transfected reporter constructs. Such artificial systems generally show a higher degree of inhibition and lower IC50 values than endogenous systems which are closer to therapeutically relevant in vivo systems. Further, in the following
- Transfecting agents are known to increase the activity of an oligonucleotide which influences the IC50 value (see for example Zhang et al., Gene Therapy, 2011, 18, 326-333; Stanton et al., Nucleic Acid Therapeutics, Vol. 22, No. 5, 2012). As artificial systems using a transfecting agent are hard or impossible to translate into therapeutic
- Example 1 Design of human CD73 antisense oligonucleotides
- Example 2 Efficacy screen of hmCD73 antisense oligonucleotides in human cancer cell lines
- hmCD73 antisense oligonucleotides of the present invention were treated with a single dose (concentration: ⁇ without addition of any transfection reagent; this process is called gymnotic delivery) of the respective antisense oligonucleotide as shown in Fig. 2A, 2B, 2C and 2D.
- human SKOV-3 human ovarian adenocarcinoma, ATCC
- 10 ⁇ of the respective antisense oligonucleotide without addition of any transfection reagent.
- control cells were treated with negl, an oligonucleotide having no sequence complementarity to any human or mouse mRNA.
- vehicle control cells were treated with medium.
- CD73 expression values were normalized to HPRT1 values and are shown relative to untreated cells (set as 1).
- hCD73 mRNA levels were reduced by >80 % by 2 of 33 tested antisense oligonucleotides in SKOV-3 cells (see Fig. 2E). Treatment with the control
- oligonucleotide neg 1 did not reduce CD73 mRNA in the three cell lines.
- Table 2 List of the mean normalized hCD73 mRNA expression values in antisense oligonucleoti de-treated A- 172 cells compared to non- treated cells of a first screening round.
- Table 3 List of the mean normalized hCD73 mRNA expression values in antisense oligonucleoti de-treated A- 172 cells compared to non-treated cells of a second screening round.
- Table 4 List of the mean normalized hCD73 mRNA expression values in antisense oligonucleotide-treated EFO-21 cells compared to non- treated cells. Relative mCD73 mRNA expression (compared to
- Example 3 Correlation analysis of antisense oligonucleotide efficacy in human EFO-21 compared to A- 172 cells and human A172 compared to mouse 4T1 cells
- SKOV-3 cells human ovarian cancer cells, ATCC
- oligonucleotide (concentrations: 10 ⁇ , 3.3 ⁇ , 1.1 ⁇ , 370 nM, 120 nM, 41 nM, 14 nM, or 4.5 nM (Fig. 4A).
- hmCD73 mRNA expression was analyzed three days later.
- the antisense oligonucleotides A05008HM (SEQ ID No. 4), A05018HM (SEQ ID No. 3) and A05028HM (SEQ ID No. 5) had the highest potency in SKOV-3 cells with regard to downregulation of hmCD73 mRNA compared to untreated cells with a maximal target inhibition of 86%, 88% and 75%, respectively.
- Table 8 ICso-values and target inhibition of selected hmCD73 antisense oligonuleotides in EFO-21 cells
- Example 5 Third screening round of hmCD73 antisense oligonucleotides in human and mouse cancer cell lines
- CD73 mRNA levels were reduced by >80 % by 11 of 13 tested ASOs in EFO- 21 cells (see Fig. 5A), by >80 % by 7 of 13 tested ASOs in SKOV-3 cells (see Fig. 5B), and by >80 % by 9 of 13 tested ASOs in 4T1 cells (see Fig. 5C).
- Treatment with the control oligonucleotide S6 did not reduce CD73 mRNA potently in the three cell lines.
- Table 9 Mean normalized hmCD73 mRNA expression values in antisense
- oligonucleotide-treated EFO-21 cells relative to untreated cells (set as 1).
- Table 10 Mean normalized hmCD73 mRNA expression values in antisense oligonucleotide-treated SKOV-3 cells relative to untreated cells (set as 1).
- Table 11 Mean normalized hmCD73 mRNA expression values in antisense
- oligonucleotide-treated 4T1 cells relative to untreated cells (set as 1).
- Example 6 IC50 determination of selected hmCD73 antisense oligonucleotides of the third screening round in EFO-21 cells (mRNA level)
- the hmCD73 antisense oligonucleotides A05038HM (SEQ ID No.42), A05041HM (SEQ ID No.45), A05042HM (SEQ ID No.45), and A05044HM (SEQ ID No.46) had shown potent single-does activity in the three cell lines EFO-21, SKOV-3 and 4T1.
- EFO-21- cells were treated with 10 ⁇ , 3.3 ⁇ , 1.1 ⁇ , 370 nM, 120 nM, 41 nM, 14 nM or 4.5 nM of the respective antisense oligonucleotide.
- the antisense oligonucleotide A05018HM that showed potent activity in the first screening round was used as reference.
- hCD73 mRNA expression was analyzed after 3 days of treatment.
- Fig. 6 depicts the concentration-dependent reduction of hCD73 expression by hmCD73 antisense oligonucleotides.
- ICso-values calculated by GraphPad Prism are shown in Table 12: mRNA inhibition [%]
- ASO IC50 (nM) ⁇ 3.33 ⁇ ⁇ . ⁇ 0.37 ⁇ 0.12 ⁇ 0.014 ⁇ 0.0045 ⁇
- Table 12 ICso-values and target inhibition of selected hmCD73 antisense oligonucleotides at titrated concentrations in EFO-21 cells
- Example 7 Concentration dependent effect on CD73 protein expression and cell viability by A05008HM (SEQ ID No. 4), A05018HM (SEQ ID No. 3) and A05028HM (SEQ ID No. 5)
- A05018HM (SEQ ID No. 3) and A05028HM (SEQ ID No. 5) were characterized in detail with regard to their knockdown efficacy on the hCD73 protein expression and their influence on cell viability at different concentrations.
- SKOV-3 cells were therefore treated with different concentrations of the respective antisense oligonucleotide for three days. Then, cells were cultivated for further three days in fresh DMEM medium containing the antisense oligonucleotide at the indicated concentration. Protein expression was analyzed by flow cytometry using the CD73 antibody (clone AD2) and 7- AAD to investigate viability. As shown in Fig.
- A05018HM (SEQ ID No. 3) did not affect viability of SKOV-3 cells in any of the conditions tested.
- Table 13 summarizes protein knockdown efficiency of the selected human CD73 antisense oligonucleotides A05008HM (SEQ ID No. 4), A05018HM (SEQ ID No. 3) and A05028HM (SEQ ID No. 5) in SKOV-3 cells:
- Example 8 Effect of CD73 protein knockdown on extracellular pyrophosphate levels in human EFO-21 and SKOV-3 cells
- Adenosine is one major immunosuppressive molecule generated during ATP degradation by hmCD73.
- Adenosine can be detected indirectly by the generation of pyrophosphate during the degradation of AMP to adenosine by a colorimetric phosphate assay kit (ab65622, abeam). Therefore, human SKOV-3 and EF021 cells were treated with 5 ⁇ antisense oligonucleotide A05018HM for 6 days (3+3). After 3 days, DMEM medium was replaced against fresh DMEM medium containing 5 ⁇ of the antisense oligonucleotide. Protein knockdown of CD73 in both tested cell lines was confirmed after 6 days by flow cytometry (Fig. 8).
- Table 14 Determination of phosphate concentration as indirect detection method for adenosine in supernatants of human EFO-21 and SKOV-3 cells after CD73 protein knockdown and after addition of exogenous AMP to the cells.
- Example 9 Investigation of the effect of hmCD73-specific antisense oligonucleotide on degradation of extracellular AMP and the conversion to adenosine by a human ovarian cancer cell line
- A05018HM had shown significant activity in suppressing hCD73 mRNA and protein expression in human cancer cells.
- the effect of hmCD73 antisense oligonucleotide treatment on the capacity to degrade extracellular AMP to immunosuppressive adenosine was investigated in EFO-21 cells.
- AMP- as well as adenosine levels can be determined by mass spectrometry.
- cells were treated with 5 ⁇ of the antisense oligonucleotide A05018HM or the control oligonucleotide S6 for a total treatment time of 6 days.
- As vehicle control cells were treated with medium only.
- CD73 protein expression was analyzed by flow cytometry after 6 days of treatment and was significantly suppressed in cells treated with A05018HM (black column) compared to cells treated with S6 (white column; Fig. 10A).
- cell culture media was replaced by PBS supplemented with 300 ⁇ of AMP after 6 days of treatment and incubated for 6.5 h.
- 300 ⁇ of AMP was added to cell-free PBS and was incubated for 6.5 h (dotted column).
- AMP and adenosine levels were determined in cell-supernatants (cell- conditioned PBS) and cell-free PBS by mass spectrometry.
- AMP-levels in cell- supernatants of untreated cells were potently reduced compared with AMP-levels in cell-free PBS (striped column; Fig. 10B), while adenosine levels were increased (Fig. IOC). This indicates a strong cell-associated capacity for conversion of AMP to adenosine.
- Table 15 Determination of relative AMP concentrations in cell supernatants relative to cell-free PBS (set as 1) after treatment of EFO-21 cells with AMP.
- Table 16 Determination of absolute adenosine concentrations in cell supernatants after treatment of EFO-21 cells with AMP.
- Example 10 Investigation of the effect of hmCD73-specific antisense oligonucleotide on T cell proliferation in the presence or absence of extracellular AMP
- FIG. 11A A05018HM treatment of CD4 + T cells potently suppressed CD73 protein expression
- Fig. 11B upper panel no differences in proliferation
- Fig. 11C absolute cell numbers
- Example 11 In vivo mCD73 mRNA knockdown by human / mouse cross-reactive CD73 antisense oligonucleotide (A05027HM) in mouse liver
- the potent hmCD73 antisense oligonucleotide A05027HM was selected and its effects on mCD73 mRNA expression in livers of Balb/c mice after systemic administration of unformulated oligonucleotide were investigated. Therefore, Balb/c mice were treated with subcutaneous injections of A05027HM at a dose of 20 mg/kg on days 1,2,3,4,5,8,10, and 12 (5 mice / group). As control, Balb/c mice were treated with vehicle (saline, six mice / group). Three days after the last antisense oligonucleotide treatment (day 15), mice were sacrificed and livers were sampled for analysis of mCD73 mRNA levels. The results depicted in Fig.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3039077A CA3039077A1 (en) | 2016-10-07 | 2017-10-09 | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 |
AU2017339581A AU2017339581A1 (en) | 2016-10-07 | 2017-10-09 | Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73 |
JP2019540697A JP2019531095A (en) | 2016-10-07 | 2017-10-09 | Immunosuppressive reversion oligonucleotide that inhibits expression of CD73 |
KR1020197013136A KR20190077390A (en) | 2016-10-07 | 2017-10-09 | An immunosuppressive-repair oligonucleotide that inhibits the expression of CD73 |
CN201780073579.6A CN110168088A (en) | 2016-10-07 | 2017-10-09 | The immunosupress of CD73 expression is inhibited to restore oligonucleotides |
EP17787366.8A EP3523436A1 (en) | 2016-10-07 | 2017-10-09 | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16192798 | 2016-10-07 | ||
EP16192798.3 | 2016-10-07 | ||
EP17187805.1 | 2017-08-24 | ||
EP17187805 | 2017-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018065627A1 true WO2018065627A1 (en) | 2018-04-12 |
Family
ID=60153282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/075682 WO2018065627A1 (en) | 2016-10-07 | 2017-10-09 | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3523436A1 (en) |
JP (1) | JP2019531095A (en) |
KR (1) | KR20190077390A (en) |
CN (1) | CN110168088A (en) |
AU (1) | AU2017339581A1 (en) |
CA (1) | CA3039077A1 (en) |
WO (1) | WO2018065627A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019144209A1 (en) * | 2018-01-24 | 2019-08-01 | Universidade Federal Do Rio Grande Do Sul | Nanometric pharmaceutical composition for release of interfering rna molecules and use thereof |
WO2021064235A1 (en) * | 2019-10-04 | 2021-04-08 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotide based ex vivo cell therapy |
WO2021170697A1 (en) | 2020-02-28 | 2021-09-02 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating cd73 exon 7 splicing |
WO2021245071A1 (en) * | 2020-06-03 | 2021-12-09 | Mv Biotherapeutics Sa | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
WO2022144439A2 (en) | 2020-12-31 | 2022-07-07 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
WO2014154843A1 (en) | 2013-03-27 | 2014-10-02 | Isarna Therapeutics Gmbh | Modified tgf-beta2 oligonucleotides |
WO2016138278A2 (en) * | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
WO2012012736A2 (en) * | 2010-07-23 | 2012-01-26 | The Ohio State University | Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway |
WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
EP3218407A1 (en) * | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
-
2017
- 2017-10-09 CA CA3039077A patent/CA3039077A1/en not_active Abandoned
- 2017-10-09 AU AU2017339581A patent/AU2017339581A1/en not_active Abandoned
- 2017-10-09 EP EP17787366.8A patent/EP3523436A1/en not_active Withdrawn
- 2017-10-09 JP JP2019540697A patent/JP2019531095A/en active Pending
- 2017-10-09 WO PCT/EP2017/075682 patent/WO2018065627A1/en unknown
- 2017-10-09 KR KR1020197013136A patent/KR20190077390A/en unknown
- 2017-10-09 CN CN201780073579.6A patent/CN110168088A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
WO2014154843A1 (en) | 2013-03-27 | 2014-10-02 | Isarna Therapeutics Gmbh | Modified tgf-beta2 oligonucleotides |
WO2016138278A2 (en) * | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
Non-Patent Citations (9)
Title |
---|
CHACKALAMANNIL; ROTELLA; WARD: "Comprehensive Modicinal Chemistry III", 3 June 2017, ELSEVIER |
DATABASE EMBL [online] 18 April 2011 (2011-04-18), "WO 2005116204-A/197253: Double strand polynucleotides generating RNA interference.", XP002768942, retrieved from EBI accession no. EM_PAT:FW790727 Database accession no. FW790727 * |
QUEZADA CLAUDIA ET AL: "5 '-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 228, no. 3, March 2013 (2013-03-01), pages 602 - 608, XP002768943, ISSN: 0021-9541 * |
STANTON ET AL., NUCLEIC ACID THERAPEUTICS, vol. 22, no. 5, 2012 |
STRUCTURE, vol. 20, 5 December 2012 (2012-12-05), pages 2161 - 2173 |
ZENKA J ET AL: "Abstracts from the 4th ImmunoTherapy of Cancer Conference", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5, no. 1, 20 March 2017 (2017-03-20) - 22 March 2017 (2017-03-22), pages 1 - 19, XP021242924, DOI: 10.1186/S40425-017-0219-4 * |
ZHANG ET AL., GENE THERAPY, vol. 18, 2011, pages 326 - 333 |
ZHAO-WEI GAO ET AL: "The Roles of CD73 in Cancer", BIOMED RESEARCH INTERNATIONAL, vol. 2014, no. 460654, 2014, pages 1 - 9, XP055361805, ISSN: 2314-6133, DOI: 10.1155/2014/460654 * |
ZOBEL H-P ET AL: "Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 49, no. 3, 2 May 2000 (2000-05-02), pages 203 - 210, XP004257158, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(00)00080-1 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019144209A1 (en) * | 2018-01-24 | 2019-08-01 | Universidade Federal Do Rio Grande Do Sul | Nanometric pharmaceutical composition for release of interfering rna molecules and use thereof |
WO2021064235A1 (en) * | 2019-10-04 | 2021-04-08 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotide based ex vivo cell therapy |
WO2021170697A1 (en) | 2020-02-28 | 2021-09-02 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating cd73 exon 7 splicing |
WO2021245071A1 (en) * | 2020-06-03 | 2021-12-09 | Mv Biotherapeutics Sa | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
WO2022144439A2 (en) | 2020-12-31 | 2022-07-07 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression |
WO2022144439A3 (en) * | 2020-12-31 | 2022-08-18 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Also Published As
Publication number | Publication date |
---|---|
CA3039077A1 (en) | 2018-04-12 |
EP3523436A1 (en) | 2019-08-14 |
AU2017339581A1 (en) | 2019-05-02 |
KR20190077390A (en) | 2019-07-03 |
CN110168088A (en) | 2019-08-23 |
JP2019531095A (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018065627A1 (en) | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd73 | |
US11959083B2 (en) | Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39 | |
US20230183708A1 (en) | PD-1-specific antisense oligonucleotide and its use in therapy | |
WO2020011909A1 (en) | Nucleic acid polymers inhibiting the expression of xbp1 | |
US20240076673A1 (en) | Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expression | |
US11781136B2 (en) | Oligonucleotide inhibiting the expression of Chop | |
US20220372482A1 (en) | Modified antisense oligonucleotide for inhibition of FoxP3 expression | |
US20220220485A1 (en) | PD-L1 antisense oligonucleotides for use in tumor treatment | |
NZ793165A (en) | Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39 | |
US20200163988A1 (en) | Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of IDO | |
US20230067620A1 (en) | Inhibitor of metadherin expression | |
US20220370408A1 (en) | Methods, compositions, kits and uses thereof targeting and/or treating vrk2 to enhance effectiveness of immune checkpoint inhibitor(s) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17787366 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3039077 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019540697 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017339581 Country of ref document: AU Date of ref document: 20171009 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197013136 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017787366 Country of ref document: EP Effective date: 20190507 |